TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35292719

Group type: EXPERIMENTAL
Intervention: Cardiology consultation
Number of subjects: 1269

Group type: COMPARATOR
Intervention: Transthoracic echocardiography (TTE)
Number of subjects: 1269
Study: 35292724

Group type: EXPERIMENTAL
Intervention: Avelumab (10 mg/kg every 2 weeks)
Number of subjects: 15
Study: 35292802

Group type: EXPERIMENTAL
Intervention: Matched targeted therapies
Number of subjects: 787

Group type: EXPERIMENTAL
Intervention: cfDNA analysis
Number of subjects: 787
Study: 35292905

Group type: EXPERIMENTAL
Intervention: Neurofeedback augmented mindfulness training (MT)
Number of subjects: 34
Study: 35292924

Group type: EXPERIMENTAL
Intervention: Ultrasound-measured jugular venous pressure (U-JVP)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Direct central venous pressure (CVP) measurement
Number of subjects: 114
Study: 35293148

Group type: EXPERIMENTAL
Intervention: ABTL0812
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paclitaxel
Number of subjects: 0
Study: 35293696

Group type: EXPERIMENTAL
Intervention: Nuclear scintigraphy
Number of subjects: 0
Study: 35293866

Group type: EXPERIMENTAL
Intervention: EPIO (eHealth self-management intervention) combined with PMP (psychomotor physiotherapy)
Number of subjects: 5
Study: 35293984

Group type: EXPERIMENTAL
Intervention: Pegloticase (8 mg biweekly infusions) + oral MTX (15 mg/week) co-therapy
Number of subjects: 2
Study: 35294044

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (VAS)
Number of subjects: 1223856
Study: 35294135

Group type: EXPERIMENTAL
Intervention: Chinese herbal medicines
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Randomized allocation
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Parallel interventional model
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Double blind masking
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Single center trials
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Ethical approval
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Phase IV trials
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Published trials
Number of subjects: 180
Study: 35294335

Group type: EXPERIMENTAL
Intervention: FCV-19S modified for application during the perinatal period
Number of subjects: 178
Study: 35294488

Group type: EXPERIMENTAL
Intervention: Assistive technology (AT) based on robotics and artificial intelligence
Number of subjects: 0
Study: 35294522

Group type: EXPERIMENTAL
Intervention: Ribociclib + binimetinib (binimetinib 45 mg twice daily + ribociclib 200 mg once daily, 21 days on/7 days off)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Ribociclib + binimetinib
Number of subjects: 41
Study: 35294527

Group type: EXPERIMENTAL
Intervention: Active surveillance (352 patients, 68.2%)
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Surgical resection (120 patients, 23.3%)
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Systemic treatments (44 patients, 8.5%)
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: CTNNB1 p.S45F mutation
Number of subjects: 516
Study: 35294625

Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 21300

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 21300
Study: 35294811

Group type: EXPERIMENTAL
Intervention: Valoctocogene roxaparvovec (AAV5-hFVIII-SQ) gene therapy, single infusion of 6×10^13 vg/kg
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Valoctocogene roxaparvovec (AAV5-hFVIII-SQ) gene therapy
Number of subjects: 134
Study: 35295414

Group type: EXPERIMENTAL
Intervention: Neuromodulation (intrathecal therapy, spinal cord stimulation, or dorsal root ganglion stimulation)
Number of subjects: 2635

Group type: COMPARATOR
Intervention: Pain medications
Number of subjects: 2635

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 2635

Group type: COMPARATOR
Intervention: Conservative treatment (medications)
Number of subjects: 2635
Study: 35295458

Group type: EXPERIMENTAL
Intervention: Sigma-1 Receptor Changes
Number of subjects: 0
Study: 35295488

Group type: EXPERIMENTAL
Intervention: Probiotic VSL#3 Treatment
Number of subjects: 0
Study: 35295526

Group type: EXPERIMENTAL
Intervention: PROMIS Sleep Short Forms
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 35295591

Group type: COMPARATOR
Intervention: cBM-MSCs (bone marrow mesenchymal stem cells from cirrhosis patients)
Number of subjects: 10

Group type: COMPARATOR
Intervention: cBM-MSCs
Number of subjects: 10
Study: 35295614

Group type: EXPERIMENTAL
Intervention: Calligraphy activity
Number of subjects: 150

Group type: COMPARATOR
Intervention: General activity
Number of subjects: 150
Study: 35295665

Group type: EXPERIMENTAL
Intervention: High doses of intravenous amoxicillin (HDIVA)
Number of subjects: 112
Study: 35295712

Group type: COMPARATOR
Intervention: High participation in nutrition-sensitive agriculture intervention
Number of subjects: 287

Group type: COMPARATOR
Intervention: Medium participation in nutrition-sensitive agriculture intervention
Number of subjects: 287
Study: 35295819

Group type: EXPERIMENTAL
Intervention: Regdanvimab 40 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regdanvimab 80 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35296017

Group type: COMPARATOR
Intervention: Regional anesthesia
Number of subjects: 0

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 0
Study: 35296254

Group type: EXPERIMENTAL
Intervention: Psychotropic drugs (PDs)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Multiple medications
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Potentially inappropriate medications
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Antipsychotics, antidepressants, and sedative substances
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Pain medication
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Antipsychotics and sedative substances
Number of subjects: 191
Study: 35296556

Group type: EXPERIMENTAL
Intervention: Neoadjuvant sintilimab plus CapeOx (oxaliplatin and capecitabine)
Number of subjects: 0
Study: 35296845

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 35296895

Group type: EXPERIMENTAL
Intervention: 10-minute Apgar score of 0
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Combination of 10-minute Apgar score with other risk variables
Number of subjects: 347
Study: 35296961

Group type: EXPERIMENTAL
Intervention: Ophthalmological treatment
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Dopatherapy reduction
Number of subjects: 82

Group type: COMPARATOR
Intervention: Visual complaints
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Evolution of visual illusions and hallucinations
Number of subjects: 82
Study: 35296975

Group type: EXPERIMENTAL
Intervention: Acute aerobic exercise (30 minutes at 60-80% of maximal heart rate)
Number of subjects: 40
Study: 35296993

Group type: EXPERIMENTAL
Intervention: Infliximab-dyyb (biosimilar to infliximab)
Number of subjects: 115
Study: 35297025

Group type: EXPERIMENTAL
Intervention: Abrocitinib 200 mg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Abrocitinib 100 mg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg subcutaneous injection every 2 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35297944

Group type: EXPERIMENTAL
Intervention: Anatomic surgical resection
Number of subjects: 2833

Group type: EXPERIMENTAL
Intervention: Adequate lymph node dissection (≥1 N1 nodal station plus ≥3 N2 nodal stations)
Number of subjects: 2833

Group type: EXPERIMENTAL
Intervention: Any adjuvant chemotherapy
Number of subjects: 2833

Group type: EXPERIMENTAL
Intervention: At least 4 cycles of adjuvant platinum-based chemotherapy
Number of subjects: 2833

Group type: EXPERIMENTAL
Intervention: Any cisplatin-based adjuvant chemotherapy
Number of subjects: 2833
Study: 35298203

Group type: EXPERIMENTAL
Intervention: Behavior Change Techniques (BCT) delivery by counselors
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Behavior Change Techniques (BCT) receipt by clients
Number of subjects: 48
Study: 35298210

Group type: EXPERIMENTAL
Intervention: Severe tinnitus
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Tinnitus-related distress factors
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Correlational analyses
Number of subjects: 112
Study: 35298296

Group type: EXPERIMENTAL
Intervention: Cabozantinib 40 mg once daily plus nivolumab 240 mg once every 2 weeks (Cohort 1)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Cabozantinib 40 mg once daily plus nivolumab 480 mg once every 4 weeks (Cohort 1)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Cabozantinib plus nivolumab (Cohort 2)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Treatment-related adverse events
Number of subjects: 47
Study: 35298394

Group type: EXPERIMENTAL
Intervention: Mobile survey (n=63)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Bidirectional SMS text messaging (n=64)
Number of subjects: 127
Study: 35298514

Group type: EXPERIMENTAL
Intervention: Implementation Facilitation (IF)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Implementation as Usual (IU)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: MISSION-Vet services
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Number of MISSION-Vet sessions
Number of subjects: 93
Study: 35298698

Group type: EXPERIMENTAL
Intervention: Cetrelimab 80, 240, 460, or 800 mg every 2 weeks (Q2W) or 480 mg Q4W (Phase 1)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Cetrelimab 240 mg Q2W (Phase 2)
Number of subjects: 58
Study: 35299035

Group type: EXPERIMENTAL
Intervention: T-DM1 (second-line treatment)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Lapatinib plus capecitabine (third or fourth-line treatment)
Number of subjects: 280
Study: 35299248

Group type: EXPERIMENTAL
Intervention: HIV-1 replication capacity (RC) of transmitted/founder viruses
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: HIV-1 subtype B isolates
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: RC measurement
Number of subjects: 355
Study: 35299273

Group type: EXPERIMENTAL
Intervention: Near-infrared (NIR) contrast agent labeled with IRDye800 administered topically to patients with Barrett's esophagus.
Number of subjects: 31
Study: 35299780

Group type: EXPERIMENTAL
Intervention: Autologous fecal microbiota transplant (aFMT)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 67
Study: 35299970

Group type: EXPERIMENTAL
Intervention: Abnormal glucose metabolism parameters (including DM, hyperinsulinemia, and insulin resistance)
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Postprandial 2 h blood glucose ≥11.1mmol/L and HbA1c ≥6.5%
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Insulin resistance
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Higher T staging
Number of subjects: 377
Study: 35300248

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 35300709

Group type: EXPERIMENTAL
Intervention: Robotic training using REAplan® robot for bimanual coordination task (CIRCUIT) over 3 consecutive days.
Number of subjects: 34

Group type: COMPARATOR
Intervention: Healthy individuals (HIs) training on the same robotic device.
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Robotic training with REAplan® robot.
Number of subjects: 34
Study: 35300885

Group type: EXPERIMENTAL
Intervention: Scary Scale (self-assessment fear scale)
Number of subjects: 544
Study: 35300897

Group type: EXPERIMENTAL
Intervention: ECMO-ICU
Number of subjects: 445

Group type: COMPARATOR
Intervention: non-ECMO-ICU
Number of subjects: 445
Study: 35301040

Group type: EXPERIMENTAL
Intervention: Pattern Electroretinogram (PERG) stimulation with reversible checkerboards, recorded every 4 weeks for 3 months
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Metric derived from PERG time series using machine learning
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Follow-up at week 12
Number of subjects: 24
Study: 35301199

Group type: EXPERIMENTAL
Intervention: VAS demand
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: VAS control
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Test-retest reliability for VAS demand and control
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: VAS cut-offs
Number of subjects: 190

Group type: COMPARATOR
Intervention: Comparison of job control
Number of subjects: 190
Study: 35301677

Group type: EXPERIMENTAL
Intervention: Deep learning (DL) based coronary artery calcium scoring (CACS)
Number of subjects: 56
Study: 35301822

Group type: EXPERIMENTAL
Intervention: Brolucizumab 6 mg intravitreal injection
Number of subjects: 14
Study: 35301985

Group type: EXPERIMENTAL
Intervention: Cardiac ablation
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: D-dimer elevated prior to procedure
Number of subjects: 80
Study: 35302268

Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Number of subjects: 109
Study: 35302402

Group type: EXPERIMENTAL
Intervention: PsA patients
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: PsO patients
Number of subjects: 149

Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 149
Study: 35302581

Group type: EXPERIMENTAL
Intervention: Remission
Number of subjects: 1684

Group type: EXPERIMENTAL
Intervention: LLDAS
Number of subjects: 1684
Study: 35302585

Group type: EXPERIMENTAL
Intervention: ARRY-382 200-400 mg QD plus pembrolizumab 2 mg/kg IV Q3W (Phase 1b)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: ARRY-382 300 mg QD plus pembrolizumab 200 mg IV Q3W (Phase 2)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Adverse events related to ARRY-382
Number of subjects: 57
Study: 35302622

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Conventional HRT
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group 1 (healthy age-matched women)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group 2 (young eumenorrheic women)
Number of subjects: 99
Study: 35302958

Group type: EXPERIMENTAL
Intervention: Neural processing associated with ventromedial prefrontal cortex activation
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Self-management cognitive processes and behaviors
Number of subjects: 16
Study: 35302959

Group type: EXPERIMENTAL
Intervention: 30-minute walk at 100 steps per minute
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Participants with knee osteoarthritis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy participants
Number of subjects: 0
Study: 35303007

Group type: EXPERIMENTAL
Intervention: CAR-T IS quality measurement using ML-based method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ML-based automated algorithm for quantifying CAR-T IS data
Number of subjects: 0
Study: 35303070

Group type: EXPERIMENTAL
Intervention: Zanubrutinib 160 mg orally twice daily
Number of subjects: 86
Study: 35303173

Group type: EXPERIMENTAL
Intervention: Microbiological culture
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Coagulase-negative staphylococci (CONS)
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Cutibacterium acnes
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Postoperative infections
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Ventral surgical approaches
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Type 2 Modic changes (MC)
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Preoperative and postoperative Oswestry Disability Index (ODI) and Neck Disability Index (NDI)
Number of subjects: 392
Study: 35303199

Group type: EXPERIMENTAL
Intervention: Mental health-focused preventive intervention
Number of subjects: 222
Study: 35303201

Group type: EXPERIMENTAL
Intervention: Activities of Daily Living (ADL) score (0=disability, 6=no disability)
Number of subjects: 2359

Group type: EXPERIMENTAL
Intervention: ADL as a continuous variable
Number of subjects: 2359

Group type: EXPERIMENTAL
Intervention: Being 'disabled' (ADL < 6)
Number of subjects: 2359
Study: 35303249

Group type: EXPERIMENTAL
Intervention: Youth VIP leadership retreats (large 'kick-off' retreat)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Youth VIP leadership retreats (smaller, focused retreats during the school year)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-attending youth
Number of subjects: 0
Study: 35303285

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVT-AFL) in a treat-and-extend regimen
Number of subjects: 210
Study: 35303517

Group type: COMPARATOR
Intervention: RNA sequencing for gene expression in males (12 SGA and 27 AGA)
Number of subjects: 74

Group type: COMPARATOR
Intervention: RNA sequencing for gene expression in females (9 SGA and 26 AGA)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Sex-combined analysis
Number of subjects: 74
Study: 35303924

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) for PPH prevention
Number of subjects: 4521
Study: 35304066

Group type: EXPERIMENTAL
Intervention: Diabetes mellitus (DM)
Number of subjects: 7839

Group type: EXPERIMENTAL
Intervention: Diabetes mellitus (DM) without AHF
Number of subjects: 7839

Group type: EXPERIMENTAL
Intervention: AHF without DM
Number of subjects: 7839

Group type: EXPERIMENTAL
Intervention: Diabetes mellitus (DM) and AHF
Number of subjects: 7839
Study: 35304622

Group type: EXPERIMENTAL
Intervention: Camrelizumab (200 mg IV on day 1), Apatinib (500 mg oral once daily), S-1 (specific dose oral for first 14 days)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Camrelizumab, Apatinib, and S-1 combination therapy
Number of subjects: 24
Study: 35304684

Group type: EXPERIMENTAL
Intervention: Adalimumab biosimilar PF-06410293 (ADL-PF) 40 mg via prefilled syringe (PFS) and single-use PFP device
Number of subjects: 50
Study: 35304729

Group type: EXPERIMENTAL
Intervention: Methylene blue photodynamic disinfection (MB-PDI)
Number of subjects: 0
Study: 35304832

Group type: EXPERIMENTAL
Intervention: First-line ICI/TKI therapy (pembrolizumab, nivolumab, avelumab, or nivolumab-ipilimumab with sunitinib, axitinib, pazopanib, lenvatinib, or cabozantinib)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Second-line ICI/TKI therapy
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Third-line ICI/TKI therapy
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Fourth-line or greater ICI/TKI therapy
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: ≥ Second-line ICI/TKI therapy in patients who received ICI only
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: ≥ Second-line ICI/TKI therapy in patients who received both TKI and ICI previously
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: ≥ Second-line ICI/TKI therapy overall
Number of subjects: 85
Study: 35304842

Group type: EXPERIMENTAL
Intervention: Online weight loss intervention
Number of subjects: 43
Study: 35305102

Group type: EXPERIMENTAL
Intervention: Toripalimab (240 mg, day 1) plus paclitaxel (135 mg/m2, day 1) and carboplatin (AUC 5 mg/mL per min, day 1) for 2 cycles
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Toripalimab plus paclitaxel and carboplatin
Number of subjects: 20
Study: 35305254

Group type: EXPERIMENTAL
Intervention: Adalimumab (Humira)
Number of subjects: 251
Study: 35305260

Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 9197

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9197
Study: 35305400

Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg intravenously every 3 weeks until loss of clinical benefit or unacceptable toxicity
Number of subjects: 474
Study: 35305556

Group type: EXPERIMENTAL
Intervention: Gentamicin
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Vancomycin
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Non-nephrotoxic antibiotic
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 46
Study: 35305589

Group type: EXPERIMENTAL
Intervention: Lights4Violence intervention
Number of subjects: 1146

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1146
Study: 35305592

Group type: EXPERIMENTAL
Intervention: Schizotypy (measured by Schizotypal Personality Questionnaire - Brief Revised (SPQ-BR))
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Quality of life (measured by Brunnsviken Brief Quality of Life Scale and the European quality of life index version 5D)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Autistic traits (measured by The Ritvo Autism, Asperger Diagnostic Scale-Revised Screen 14 items)
Number of subjects: 110
Study: 35305596

Group type: EXPERIMENTAL
Intervention: Dacomitinib (45 mg/day)
Number of subjects: 30
Study: 35305599

Group type: EXPERIMENTAL
Intervention: Pooled Cohort Equations (PCE)
Number of subjects: 1345

Group type: EXPERIMENTAL
Intervention: Adjusted PCE with updated cohorts
Number of subjects: 1345

Group type: EXPERIMENTAL
Intervention: Framingham CVD Lipids
Number of subjects: 1345

Group type: EXPERIMENTAL
Intervention: Framingham CVD Body Mass Index (BMI)
Number of subjects: 1345

Group type: EXPERIMENTAL
Intervention: WHO Lipids
Number of subjects: 1345

Group type: EXPERIMENTAL
Intervention: WHO BMI
Number of subjects: 1345

Group type: EXPERIMENTAL
Intervention: PCE model
Number of subjects: 1345
Study: 35305740

Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S vaccine (Johnson & Johnson), single dose of 5×10^10 viral particles
Number of subjects: 477102
Study: 35305850

Group type: EXPERIMENTAL
Intervention: Emergency department assessment for nonhospitalized injuries
Number of subjects: 2919

Group type: EXPERIMENTAL
Intervention: Baseline determinants of functional decline
Number of subjects: 2919
Study: 35305895

Group type: EXPERIMENTAL
Intervention: ChAdOx1/mRNA-1273 (8 weeks apart)
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: ChAdOx1/mRNA-1273 (4 weeks apart)
Number of subjects: 399

Group type: COMPARATOR
Intervention: ChAdOx1/ChAdOx1 (8 weeks apart)
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: mRNA-1273/mRNA-1273 (4 weeks apart)
Number of subjects: 399
Study: 35305920

Group type: EXPERIMENTAL
Intervention: Perampanel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 35306029

Group type: EXPERIMENTAL
Intervention: Conservative treatment (non-stent)
Number of subjects: 23
Study: 35306487

Group type: EXPERIMENTAL
Intervention: Transimpedance Matrix Algorithm for detecting tip fold-over (TFO)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Transimpedance Matrix Algorithm
Number of subjects: 157